Tuttle Ventures Newsletter

Share this post
Tuttle Ventures Scores Early Win
newsletter.tuttleventures.com

Tuttle Ventures Scores Early Win

Actionable Market Insights from Darin Tuttle | Vision | Courage | Patience

Tuttle_Ventures
Jun 8, 2021
1
Share this post
Tuttle Ventures Scores Early Win
newsletter.tuttleventures.com

Yesterday, Biogen Inc., ticker symbol BIIB, gained 38% in 1 DAY on news of FDA approval of a new drug to fight Alzheimer’s.

At Tuttle Ventures, we could not BE MORE EXCITED. We took notice of this company back in April, before any of the headlines had a clue.

When you look for great companies at fair prices, you choose to focus on SUBSTANCE over STYLE.

Our high conviction wasn’t based solely on the approval of the new experimental drug but also the R&D culture in neurology, wide operating margins, and potential growth opportunities in biosimilar businesses.

We continue to believe that Biogen Inc., is a future healthcare leader in an innovative field.

This demonstrates Tuttle Ventures investment philosophy:
Vision | Courage | Patience

Click on the link to request to download our latest pitch deck or visit our website to learn more.

If you didn’t see the latest Yahoo! Finance news article check it out here.

—Best,

Darin Tuttle

Founder

Tuttle Ventures, LLC

No alternative text description for this image
No alternative text description for this image
No alternative text description for this image
Share this post
Tuttle Ventures Scores Early Win
newsletter.tuttleventures.com
Comments

Create your profile

0 subscriptions will be displayed on your profile (edit)

Skip for now

Only paid subscribers can comment on this post

Already a paid subscriber? Sign in

Check your email

For your security, we need to re-authenticate you.

Click the link we sent to , or click here to sign in.

TopNewCommunity

No posts

Ready for more?

© 2022 Tuttle Ventures LLC
Privacy ∙ Terms ∙ Collection notice
Publish on Substack Get the app
Substack is the home for great writing